CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


INOpulseWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2745 assessment of the sequelae after hospitalization for Sars-COV-2 Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.

NCT04421508 COVID-19 Coronavirus Coronavirus Infection Combination Product: INOpulse Combination Product: Placebo
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Measure: The proportion of subjects who died or had respiratory failure

Time: Through Day 28

Secondary Outcomes

Description: The assessment of clinical status at the first assessment of a study day. The scale is: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.

Measure: Clinical status using National Institute of Allergy and Infectious Diseases (NIAID) 8-point ordinal scale

Time: Day 7, 14, 28 and day of discharge

Measure: Proportion of subject to recover, defined as return to room air or baseline O2, or discharged alive

Time: Through Day 28

Measure: Proportion of subjects discharged alive from hospital

Time: Through Day 28

Measure: Duration of Hospitalization

Time: Through Day 28

Measure: Mortality - all cause and cardiopulmonary

Time: Through Day 28

Measure: Proportion of subjects with a negative conversion of reverse transcription polymerase chain reaction (RT-PCR) from a nasopharyngeal swab

Time: Through Day 28

Other Outcomes

Measure: Proportion of subjects with adverse events leading to study drug discontinuation

Time: Through Day 28


No related HPO nodes (Using clinical trials)